Mar 17, 2025
Clario announces acquisition of imaging provider NeuroRx
Feb 23, 2021
NeuroRx Announces that ZYESAMI(TM) (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint
Feb 09, 2021
NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI(TM) (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19
Feb 09, 2021
NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI(TM) in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19
Feb 03, 2021
NeuroRx Initiates Phase 2/3 Study of Inhaled ZYESAMI(TM) for Severe COVID-19 with UCI Health
Jan 11, 2021
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI(TM) (RLF-100(TM): aviptadil) in the I-SPY COVID-19 Trial
Dec 30, 2020
NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
Nov 24, 2020
NeuroRx and Relief announce initial successful results from expanded access use of RLF-100(TM) (aviptadil) in patients with Critical COVID-19 and Severe Comorbidity: 72% survival seen in ICU patients
Nov 13, 2020
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
Nov 05, 2020
NeuroRx and Relief Therapeutics announce continuation of RLF-100(TM) trial for treatment of COVID-19 Respiratory Failure: Trial is on track to complete enrollment in 2020
Nov 04, 2020
NeuroRx Receives Notice of Allowance from USPTO for a Formulation for the Treatment of Post-Traumatic Stress Disorder
Sep 30, 2020
NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100(TM) (aviptadil)
Sep 23, 2020
NeuroRx submits request for Emergency Use Authorization for RLF-100(TM) (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy
Mar 26, 2020
RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress